RSS Feed

Draft H2020 Work Programmes 2018-2020


The European Commission is currently making public the draft work programmes 2018-2020 for most of the thematic programmes in Horizon 2020. These drafts are available before their adoption to provide potential participants with the currently expected main lines of the work programmes. The remaining drafts are expected to be released this week.

Please note that they are still in a DRAFT version and as such have not been adopted or endorsed by the European Commission. Any views expressed are the views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission.

The adoption of the work programme will be announced on the Horizon 2020 website and on the Participant Portal towards end of October 2017. Only the adopted work programmes will have legal value. Information and topic descriptions indicated in these drafts may not appear in the final work programme; and likewise, new elements may be introduced at a later stage.

More information and links to the draft work programmes can be found on the EC website.  

Sources: EC, Euresearch

Innovative Medicines Initiative (IMI): evaluations of IMI1 and IMI2

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;
- the quality of the research emerging from IMI projects;
- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation
Read the new IMI brochure on results and impacts

Source: IMI

Swiss wins 2017 Nobel Prize in chemistry

Jacques Dubochet of Switzerland's University of Lausanne has been awarded this year’s Nobel prize in chemistry together with two other scientists from Britain and the United States.

Announcing the winners on Wednesday, the Royal Swedish Academy of Sciences said the three scientists helped develop cryo-electron microscopy - a method to have detailed images of life’s complex machineries in atomic resolution.

Dubochet, born in 1942, is a honorary professor of biophysics at Lausanne University and worked at Basel and Geneva Universities.

Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Federated and privacy-preserving machine learning in support of drug discovery
- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2

Evolution of the European framework programme

The European Parliament released an in-depth analysis on the advancement of and key data from FP1 to Horizon 2020 in view of FP9.

This paper aims to provide an overview of the evolution of the EU framework programme for research and innovation. The paper focuses on the evolution of the legal basis to adopt the programme, its structure and its budget. It then highlights key issues that will have to be addressed in the coming years in the discussion leading to the adoption of the ninth framework programme.

10 years ERC, 10 portraits

In 10 years, The European research council ERC has funded more than 1000 researchers across Europe. Discover here some of them. 


First Swiss start-ups receive financial support from Horizon 2020 SME instrument

Four Swiss start-ups will receive CHF 50’000 each through the Horizon 2020 SME instrument scheme. The instrument, provided with about € 3 billion, is accessible to Swiss SMEs since January 2017. Next application deadline is 6 September.

Since January 2017, Swiss researchers and organisations are able to fully participate in Horizon 2020, the European Union's research and innovation funding programme. Since then Swiss SME including start-ups are eligible to apply for the Horizon 2020 SME instrument. Provided with about € 3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.

This week the first Swiss companies were announced which were selected for funding through the SME instrument. These include:

AMPHIRO (Cleantech): connected shower consumption meters

Daedalean (ICT): autonomous flight control for the electric personal aircraft of the near future

DEPsys (Cleantech): smart grid optimisation platform

SENSARS NEUROPROSTHETICS (Medtech): neuroprosthetic device allowing amputees to feel again from missing limbs

Each project will receive €50’000 to finance a feasibility study for innovative products that can disrupt the market. Companies also receive business support services and up to three days of free business coaching.

These companies were selected for a Phase 1 project and may in future apply for a Phase 2 financing scheme, allowing to benefit from a further financing - up to €2.5M - for activities focusing on bringing innovative ideas (product, process, service etc.) to industrial readiness and maturity for market introduction, focusing on demonstration, testing, prototyping, piloting, scaling-up, miniaturization, design, market replication and the like.

SCIPROM will be pleased to support Swiss SMEs in the preparation of proposals for the SME instrument, together with our business partner Inspiralia, a Spanish company which has long-term experience in the SME instrument and supported DEPsys in their SME instrument proposal prepation. 
Source: http://www.startupticker.ch



Largest ever shared data repository for researchers

World-leading research institutes have agreed to join forces with funding agencies and policy makers to create the European Open Science Cloud, the largest shared data repository in history.

The idea is to give every scientific user access to the data resulting from research carried out with public funding, using a single login.

Vice-versa, this shared repository will provide researchers involved in publically funded research projects with a suitable data base to share their research data as required by the funding agencies.

Source: Horizon, the EU Research and Innovation Magazine - EC DG RTDi

SME Instrument increases a company's innovation capacity

The European Commission (EC) published the ‘Accelerating innovation in Europe: Horizon 2020 SME Instrument Impact’ report.

According to the report, participating in the Horizon 2020 SME Instrument leads to a growth of the innovation capacity of companies and attracts investment. Regarding attracting private investment, companies that benefited from the SME Instrument manage to obtain their next investment 18 months faster than non-SME Instrument beneficiaries do. The SME Instrument support already resulted in two stock market launches and several prizes. Unfortunately, due to the Swiss former partial association in Horizon 2020, the report does not make mention of Swiss companies participating in and benefiting from the SME Instrument.

The SME Instrument funded 2'457 companies and attracts small companies of all sizes, ages, profiles and sectors. It attracts both young, market challenging start-ups aiming for fast scale-up as well as family businesses existing since many years, where the new generation of owners bet on innovation to remain competitive. In addition, university spin-offs use the SME Instrument, especially Phase 1, to test the market feasibility of their technologies. SMEs from Spain and Italy account for one third of both applicants and funded companies. Together with the UK, these three countries represent almost half (47%) of all funded SMEs. However, the highest success rates are achieved in Iceland (20%), Austria (13%), Denmark (13%), Ireland (13%) and Sweden (12%). Moreover, there is a strong correlation between geographical distribution and innovation hubs across Europe: The SME Instrument's geographical distribution matches the main innovation hubs in Europe, including London, Berlin, Dublin, Paris, Amsterdam and Munich. These hubs bring together innovative companies, like accelerators, incubators and co-working spaces, investors and highly skilled individuals, but also friendly tax regimes and requirements for setting up a business.

In the first three years, more than 31'000 applications were handed in and approximately 2'500 companies received funding. Until 2020, the EC will invest three billion Euros in companies. The SME Instrument itself will be revamped in the Horizon 2020 work programme 2018-2020, making it fully bottom-up, focusing on breakthrough innovations, thus attempting to attract more young, market challenging start-ups aiming for fast scale-up.

Sources: Swisscore, EC

H2020 interim evaluation

Halfway down the Horizon 2020 road, the European Commission (EC) has taken stock of the implementation of Horizon 2020 so far. The EC published the Staff Working Document (SWD) on the interim evaluation of Horizon 2020 and aims to make adjustments in such a way that it will contribute to improving the implementation of Horizon 2020 in its last Work Programme 2018-2020.

Areas which have been indentified where Horizon 2020 and its successor would need to increase their efforts include:
  
- Underfunding, which has led to massive oversubscription across the board in the whole of Horizon 2020. In addition, it resulted in an enormous waste of resources for applicants and of good proposals for Europe. 
- Better support for breakthrough, market-creating innovation is needed. To this aim, a European Innovation Council (EIC) shall be created in the next Framework Programme.

- Greater outreach to civil society in terms of better explaining results and impacts, but also in involving them better in the programme co-design (agenda-setting) and its implementation (co-creation).

More information can be found on the Swisscore website and the European Commission's news ticker. 

Source: Swisscore, EC
See Older Posts...